DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
NCT ID: NCT02252653
Last Updated: 2016-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1010 participants
OBSERVATIONAL
2014-06-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology
NCT03190577
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm
NCT02256163
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
NCT05489549
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
NCT01604122
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
NCT06896266
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Familial Amyloidotic Cardiomyopathy (FAC)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of evidence suggestive of cardiac amyloidosis
* Subject is willing and able to comply with protocol required assessments and provide written informed consent
Exclusion Criteria
* Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
* Patient is currently pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jared Gollob, MD
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Little Rock, Arkansas, United States
Clinical Trial Site
Bakersfield, California, United States
Clinical Trial Site
La Mesa, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Torrance, California, United States
Clinical Trial Site
Aurora, Colorado, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Tampa, Florida, United States
Clinical Trial Site
Athens, Georgia, United States
Clinical Trial Site
Atlanta, Georgia, United States
Clinical Trial Site
Atlanta, Georgia, United States
Clinical Trial Site
Macon, Georgia, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Merrillville, Indiana, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Springfield, Massachusetts, United States
Clinical Trial Site
Detroit, Michigan, United States
Clinical Trial Site
Jackson, Mississippi, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
Camden, New Jersey, United States
Clinical Trial Site
Rochester, New York, United States
Clinical Trial Site
Rosedale, New York, United States
Clinical Trial Site
The Bronx, New York, United States
Clinical Trial Site
Williamsville, New York, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Cleveland, Ohio, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Clinical Trial Site
Charleston, South Carolina, United States
Clinical Trial Site
Fort Worth, Texas, United States
Clinical Trial Site
Plano, Texas, United States
Clinical Trial Site
Falls Church, Virginia, United States
Clinical Trial Site
Norfolk, Virginia, United States
Clinical Trial Site
Richmond, Virginia, United States
Clinical Trial Site
Richmond, Virginia, United States
Clinical Trial Site
Anderlecht, , Belgium
Clinical Trial Site
Brussels, , Belgium
Clinical Trial Site
Hasselt, , Belgium
Clinical Trial Site
Roeselare, , Belgium
Clinical Trial Site
Blumenau, , Brazil
Clinical Trial Site
Bordeaux, , France
Clinical Trial Site
Toulouse, , France
Clinical Trial Site
Vandœuvre-lès-Nancy, , France
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Madrid, , Spain
Clinical Trial Site
Seville, , Spain
Clinical Trial Site
Cardiff, , United Kingdom
Clinical Trial Site
London, , United Kingdom
Clinical Trial Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-TTR-NT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.